8-K: Cardiff Oncology Q3 2026: Promising mCRC Data, Phase 3 Prep

Cardiff Oncology reported third quarter 2026 results, highlighting encouraging progression-free survival data for onvansertib in first-line RAS-mutated mCRC and preparations for a registrational Phase 3 trial.

Summary

• Cardiff Oncology announced its third quarter 2026 financial results and provided a business update.
• The Phase 2 trial for onvansertib in first-line RAS-mutated mCRC is ongoing, with the 30 mg onvansertib + FOLFIRI/bev arm showing a median Progression-Free Survival (PFS) that has not yet been reached, compared to approximately 11 months for the combined Standard of Care (SoC) arms.
• Patients remaining on the 30 mg onvansertib + FOLFIRI/bev arm have been on treatment for at least 21 months.
• The company is preparing for a registrational Phase 3 trial, with a potential start in Q1 2027.
• In July 2026, the company raised approximately $9.1 million in net proceeds from a registered direct offering.
• In September 2026, disputes with licensor Nerviano Medical Sciences (NMS) regarding global rights to onvansertib were resolved, and the license agreement was amended.
• Leila Alland, MD, was appointed interim Chief Medical Officer in October 2026.
• As of September 30, 2026, the company had $33.8 million in cash, cash equivalents, and short-term investments, with sufficient resources projected to fund operations through the end of Q3 2027.
• Total operating expenses for the nine months ended September 30, 2026, were $32.0 million, a decrease from $41.5 million in the same period of 2025, primarily due to reduced R&D expenses.
• Net loss for the nine months ended September 30, 2026, was $30.4 million, an improvement from $38.6 million in the prior year period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, driven by encouraging clinical trial data and strategic progress, though tempered by ongoing cash burn and the inherent risks of drug development.

Positives

• Encouraging clinical data from the Phase 2 trial showing a median PFS not reached in the onvansertib + FOLFIRI/bev arm, significantly outperforming the SoC arms (median PFS ~11 months).
• Patients on the 30 mg onvansertib + FOLFIRI/bev arm have demonstrated long-term treatment duration, exceeding 21 months.
• Active preparation for a registrational Phase 3 trial in first-line RAS-mutated mCRC, addressing a significant unmet medical need.
• Resolution of all outstanding disputes with licensor Nerviano Medical Sciences (NMS) regarding global rights to onvansertib.
• Appointment of Leila Alland, MD, as interim Chief Medical Officer, bringing extensive oncology executive experience.
• Projected cash runway sufficient to fund operations through the end of Q3 2027.
• Reduction in total operating expenses for the nine months ended September 30, 2026, driven by decreased R&D costs.
• Improved net loss for the nine months ended September 30, 2026, compared to the same period in 2025.

Negatives

• Net cash used in operating activities increased by $2.0 million for the nine months ended September 30, 2026, compared to the same period in 2025.
• The company raised $9.1 million in July 2026, indicating a need for capital to support operations.
• Selling, general, and administrative (SG&A) expenses increased by $3.1 million for the nine months ended September 30, 2026, due to legal fees and severance costs.
• The company is still in clinical development, with no approved therapies, and faces significant regulatory and market risks.

Risks

• Uncertainties associated with clinical development and regulatory approvals for onvansertib.
• The possibility that earlier clinical study results may not be predictive of future results.
• Risks related to the timing, initiation, conduct, and completion of clinical trials, including the upcoming Phase 3 trial.
• The Company's ongoing need for additional financing to support operations and development.
• Dependence on key personnel and third parties.
• Competition in the oncology market.
• Intellectual property risks.
• The potential for onvansertib to not receive regulatory approval or prove commercially successful.

Future Outlook

The company is preparing for a registrational Phase 3 trial in first-line RAS-mutated mCRC, with a potential start in Q1 2027. Management believes its current cash resources are sufficient to fund operations through the end of the third quarter of 2027.

Management Comments

• "We are greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms."
• "Building on the strength of these data, we are actively preparing for our upcoming registrational trial."
• "There are currently no treatment options specifically approved for patients with pan RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients."

Industry Context

StockSavvy.ai notes that Cardiff Oncology is operating in the highly competitive and rapidly evolving oncology drug development space. The focus on RAS-mutated mCRC addresses a significant unmet need, and the positive PFS data, if validated in Phase 3, could position onvansertib as a key therapy. The company's progress aligns with industry trends of targeted therapies and combination treatments for difficult-to-treat cancers.

Comparison to Industry Standards

• The median PFS of approximately 11 months in the combined SoC arms of the Phase 2 trial is consistent with historical benchmarks for first-line treatment of RAS-mutated mCRC.
• The non-reached median PFS in the onvansertib + FOLFIRI/bev arm represents a significant potential improvement over current industry standards for this patient population.
• The company's cash runway projection to Q3 2027 is a critical metric for clinical-stage biotech companies, and its current cash position is being monitored against its burn rate, a common industry practice.

Management Changes

Legal Proceedings

• Resolved all outstanding disputes with licensor Nerviano Medical Sciences (NMS) regarding global rights to onvansertib in September 2026.

Stakeholder Impact

• Shareholders: Potential for increased value if onvansertib proves successful in Phase 3 trials and gains regulatory approval. Dilution risk from past and potential future capital raises.
• Patients: Potential for a new, effective treatment option for RAS-mutated mCRC, addressing a significant unmet need.
• Employees: Continued employment and potential for growth tied to the company's development milestones.
• Creditors: The company's cash position and runway are key indicators for financial stability.

Next Steps

• Prepare for and initiate a registrational Phase 3 trial in first-line RAS-mutated mCRC, with a potential start in Q1 2027.
• Present updated data from an investigator-sponsored clinical trial in CMML at the American Society of Hematology (ASH) Annual Meeting on December 13, 2026.
• Management to present at the UBS Global Biopharma Conference on November 16-17, 2026.

Key Dates

Recommendation

The encouraging clinical data and strategic progress warrant a hold. However, the inherent risks of drug development, the need for further financing, and the long path to potential commercialization suggest caution. Investors should await Phase 3 results and regulatory outcomes before considering a stronger position.

Keywords

onvansertib, RAS-mutated mCRC, metastatic colorectal cancer, PLK1 inhibition, Phase 3 trial, clinical-stage biotechnology, progression-free survival, oncology